Biote names Bob Peterson interim CEO as Bret Christensen steps down

Biote Corp. (NASDAQ: BTMD) announced that Bob Peterson, the company's chief financial officer and chief business officer, will serve as interim CEO effective June 8, 2026. Current CEO Bret Christensen is stepping down for family and personal reasons but will remain on the board of directors.

Marc Beer, Biote's chairman, will assume the role of executive chairman. The Irving, Texas-based hormone optimization company said Peterson was recently promoted to an expanded role that includes chief business officer responsibilities alongside his CFO duties.

Peterson has been involved in the company's financial strategy, operational scaling, and integration of Asteria Health, according to the announcement. The board of directors has retained an executive search firm to identify CFO candidates.

"I appreciate the confidence of our Board of Directors and am honored to lead our talented team as we pursue our collective goal of becoming the leading provider of evidence-based therapeutic wellness solutions," Peterson said in a statement.

Christensen said the decision to step down was made after thoughtful consideration to prioritize family and personal matters. He expressed confidence in the company's strategy and leadership team.

The company reaffirmed its 2026 financial guidance, projecting revenue above $190 million and adjusted EBITDA above $38 million. Biote also expects a return to procedure revenue growth in the second half of the year.

Over the past year, Biote has strengthened its commercial organization, expanded its sales team, and enhanced practitioner support as part of its growth strategy. The company provides hormone optimization and healthy aging solutions through a network of certified providers.

You May Also Be Interested In

• Matinas BioPharma to merge with GH Power, sell drug unit to Azurity
• Research Alliance Corporation IV prices $75M IPO on Nasdaq
• FDA accepts BioMarin's application for full approval of achondroplasia drug